Evidence map›Paper›PMID 36880188›Full record

Trial reportCurrent radiopharmaceuticals2023

World's First Experience of the Low-Dose Radionuclide Inhalation Therapy in the Treatment of COVID-19-Associated Viral Pneumonia: Phase 1/2 Clinical Trial.

Peter Shegay, Alexey Leontyev, Denis Baranovskii, German Davydov, Marina Poluektova, Lyudmila Grivtsova, Vasily Petriev, Valeriy Stepanenko, Igor Gulidov, Valeriy Krylov and 9 more

Open access · greenAbstract readRandomized Controlled TrialClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Current radiopharmaceuticals, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Peter ShegayCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Alexey LeontyevCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Denis BaranovskiiCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
German DavydovCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Marina PoluektovaCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Lyudmila GrivtsovaCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Vasily PetrievCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Valeriy StepanenkoCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Igor GulidovCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Valeriy KrylovCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Svetlana OsadchayaCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Vladimir PetrovCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Maria SedovaCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Mikhail VekilyanCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Olga KrasilnikovaCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Sergey MorozovResearch and Practical Center of Medical Radiology, Department of Health Care of Moscow, Moscow, Russia.
Sergey IvanovCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Ilya KlabukovCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Andrey KaprinCenter of Innovative Radiological and Regenerative Technologies, National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, Obninsk, Russia.
Ministry of Health of the Russian Federation · RUPeoples' Friendship University of Russia · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivePreviously, low-dose radiation therapy was used for pneumonia treatment. We aimed to investigate the safety and effectiveness of carbon nanoparticles labeled with Technetium isotope (

methodsWe enrolled 47 patients with confirmed COVID-19 infection and early laboratory signs of cytokine storm and randomized them into the Treatment and Control groups. We analyzed blood parameters reflecting the COVID-19 severity and inflammatory response.

resultsLow-dose

conclusionInhalation low-dose radionuclide therapy of

Indexed as

COVID-19HumansRadioisotopesRadiopharmaceuticalsRespiratory Aerosols and DropletsRespiratory TherapyRadioisotopesRadiopharmaceuticalsCOVID-19Low-dosepneumonia.radionuclide therapyradiopharmaceuticalssodium pertechnetate Tc<sup>99m</sup>

Identifiers

PMID36880188
PMCPMC11851150
OpenAlexW4323348045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.